Insy Flying Completes Angel Funding Round to Propel Wireless Innovation in Minimally Invasive Healthcare

VCBeat has exclusively learned that the intelligent wireless endoscope manufacturerSuzhou InSight Medical Technology Co., Ltd.(hereinafter referred to as“Yingsai Feiying”) completed its angel round of financing. Investors includeGuoqian Venture Capital, JieLi FundandSuzhou Medical Device Industry Group. This round of funding will be used for R&D investment in the company's core products—intelligent wireless rigid and flexible endoscopes—as well as for production capacity expansion and market development.

Yingsai Feiying was established in June 2023 and is located in the Jiangsu Medical Device Technology Industrial Park (Medpark) in Suzhou High-Tech Zone. Its R&D team consists primarily of Ph.D. holders from Shanghai Jiao Tong University. This team has collaborated extensively with clinical partners, participated in numerous national, provincial, and municipal research projects, and consistently advanced the translation of scientific achievements into practical applications. The company is dedicated to the research and development, manufacturing, and sales of high-end medical devices for minimally invasive surgery, and has currently laid out its strategic presence inSmart Wireless Rigid EndoscopeandFlexible Endoscope SystemTwo innovative product series, independently developedWireless System Solutions, offering a comprehensive suite of diagnostic and therapeutic solutions featuring portable and mobile advantages, including wireless endoscopy and wireless ultrasound.

InSight’s intelligent wireless endoscopy product reduces the size of traditional image processing host units to one-twentieth, transforming it into a handheld device free from cable constraints. Leveraging advanced ultra-low-latency wireless image transmission technology and ISP tuning techniques, the product achieves latency levels and image clarity comparable to those of traditional wired endoscopy systems at both 4K and 1080P resolutions.

While meeting the demands of clinical surgeries, it significantly enhances operational convenience for physicians. Featuring wireless connectivity, ultra-low latency, portability, high-definition imaging, and accurate color reproduction, the system is also suitable for bedside diagnostic examinations in wards, emergency departments, and intensive care units (ICUs), and provides minimally invasive diagnostic and therapeutic services for battlefield and disaster relief scenarios. Leveraging cloud-based intraoperative interaction capabilities, it breaks down geographical barriers to achieve seamless interconnectivity, providing real-time technical support for remote expert consultations and surgical guidance. In the rapidly growing companion animal and livestock sectors, this system disrupts traditional diagnostic and treatment models, significantly advancing the development of precise, minimally invasive veterinary medicine.

It is reported that,The company's two core products have completed development and entered the clinical trial phase. Regulatory approval is expected in the second half of 2024.

Regarding securing this round of financing,Dr. Meng Fan, CEO of InSight ImagingIt stated: “As an essential product for minimally invasive diagnosis and treatment, endoscopes are showing a clear trend toward miniaturization and wireless connectivity. Without altering physicians’ existing workflows, this approach not only addresses the limitations of bulky wired equipment in operating rooms—such as restricted maneuverability, cumbersome operation, and difficult sterilization—but is also well-suited for expansion into lower-tier healthcare markets, thereby promoting the widespread adoption of minimally invasive procedures and offering broad market prospects. Currently, the company has established in-depth collaborations with many renowned Grade A tertiary hospitals in China, including Shanghai Jiao Tong University School of Medicine, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Changzheng Hospital, Shanghai General Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the General Hospital of the Eastern Theater Command, Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, and Xiangya Hospital of Central South University. The company’s products have been extensively trialed and clinically endorsed across departments such as urology, obstetrics and gynecology, and orthopedics at these institutions. With the support of investors in this funding round, the entire team will accelerate product R&D and manufacturing, apply the concept of wireless convenience to various medical scenarios, and rapidly establish itself as the leading brand in wireless minimally invasive diagnosis and treatment.””

Chen Hao, Partner at Guoqian Venture Capital“Minimally invasive surgery represents a key developmental trend, with medical endoscopes serving as the core medical devices in this field. InSight Imaging has been dedicated to full-stack innovation of medical endoscope products, establishing significant competitive barriers in areas such as wireless image transmission and modular integration, thereby earning high recognition from distribution channels and clinicians. Its core products hold a leading position in the industry and have already achieved commercialization. The team boasts extensive domestic and international resources, demonstrating strong execution capabilities and high efficiency. Upon completion of this financing round, the company will launch a series of innovative products to benefit more patients both domestically and abroad.”

Liu Chunsong, Managing Partner of Relay Fund“It stated: ‘The wireless endoscope products developed and manufactured by Insai Feiying have accumulated strengths in both technology and market. The founder has serial entrepreneurship experience and has built a core team with diverse backgrounds and complementary capabilities. Leveraging years of technical accumulation in robotics and military projects, the team has solved core challenges in image transmission technology. More importantly, starting from the pain points in specific clinical usage scenarios, they have driven technological innovation and rapid product iteration. The products have already been deployed in multiple hospitals, achieving a significant volume of use and establishing a leading advantage.’”

Niu Qiang, Head of the Investment Management Department, Suzhou Medical Device Industry Group“The company stated: ‘As a leading enterprise in the field of medical wireless endoscopy, InSight Imaging has been committed to promoting minimally invasive surgery, continuously developing and manufacturing innovative and competitive wireless endoscopic products. The core team of InSight Imaging possesses extensive technical expertise and industry experience, enabling it to closely align with the specific needs of clinicians through continuous technological innovation and product iteration. Meanwhile, strong channel partnerships and high recognition from clinicians have provided robust support for the company’s market expansion and brand building. Looking ahead, with the concerted efforts of all employees, InSight Imaging is confident in maintaining its technological leadership, launching more innovative products, achieving scaled growth, driving revolutionary changes in the traditional endoscopy market, and becoming a leader in the field of wireless minimally invasive diagnosis and treatment.’”

Guoqian Medical is dedicated to investing in innovative medical device technologies, startup incubation, and precision empowerment. Its wholly-owned subsidiary, Guoqian Venture Technology (Suzhou) Co., Ltd., is a venture capital firm specializing in early-stage equity investments in the medical device sector. Guided by its business philosophy of “helping others achieve their dreams,” Guoqian Venture Capital conducts industrial investment and consolidation through managed equity investment funds, while Guoqian Medical builds an industrial ecosystem through incubation and empowerment. The two business platforms work in close synergy to establish a high-end medical device industry cluster and ecosystem in Suzhou New District.

Jieli Fund, established in 2009, is a venture capital institution dedicated to investing in technology-driven startups. The fund is capitalized by the Venture Capital Guidance Fund of the Ministry of Science and Technology, the China International Capital Corporation Qiyuan National Emerging Industry Venture Capital Guidance Fund, the Shanghai Venture Capital Guidance Fund, the Science and Technology Innovation Investment Fund of Funds, as well as market-oriented investors. It focuses primarily on sectors such as new materials, healthcare, intelligent manufacturing, and related services. Jieli Fund currently manages six funds with a total scale exceeding RMB 1.6 billion and has invested in nearly 150 early- to mid-stage technology startups since its inception. Jieli Fund serves as a council member of the Shanghai Venture Capital Industry Association and holds leading roles including the convening unit of the New Materials Professional Committee under the Ministry of Science and Technology’s Venture Capital Alliance, and the rotating chairman unit of the Shanghai New Materials Industry Investment Alliance.

As an angel investor in the first round, Relay Fund invested in companies such as Titan Scientific (688133), Haoyuan Pharmchem (688131), Uni-Vanguard (301166), and Hongying Intelligence (001266), helping them achieve successful IPOs. Over the years, it has repeatedly been honored by Zero2IPO Research, China Venture, and the China Fund of Funds Summit with awards including “Top 10 Chinese Early-Stage Funds by Annual Return,” “Top 30 Best Early-Stage Venture Capital Firms in China,” “Top 10 National-Level Private Equity Funds in Mass Entrepreneurship and Innovation,” and “Top 30 Early-Stage Funds by Best Return at the China Fund of Funds Summit.”

Jiangsu Medical Device Technology Industrial Park (Medpark) is a national-level medical device technology industrial park jointly established by the Suzhou New District and the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences. The park is operated by Suzhou Medical Device Industry Development Group Co., Ltd., which coordinates resources within the Suzhou New District. Leveraging three core capabilities—carrier development and construction, park operation, and industrial investment—the park focuses on the development of the medical device industry. Medpark has comprehensively reviewed the industry’s development landscape, targeting five key sectors including in vitro diagnostics, high-end implantable devices, high-end medical imaging, and digital healthcare. By harnessing the driving force of leading enterprises and research institute platforms, it accelerates the incubation of high-quality projects.Over the past decade, Medpark has remained dedicated to advancing the medical device industry, striving to build a unique, leading, and iconic highland for high-end medical devices. It has successively received national honors such as the National Torch Program Characteristic Industrial Base for Medical Devices, Pilot Cluster for Innovative Medical Devices, National-Level Professional Incubator for Medical Devices, and Demonstration Unit for the Construction of National-Level Sci-Tech Entrepreneurship Incubation Chains. Currently, the park has gathered more than 1,100 companies related to medical devices and biopharmaceuticals. Looking ahead, Medpark will continue to uphold digital leadership, innovation-driven growth, and cluster-based development, strengthening industrial competitiveness and highlighting distinctive advantages. It aims to accelerate enterprises’ entry into capital markets, make greater contributions to building an innovative cluster for high-end medical devices in the Suzhou New District, and evolve into a demonstration zone for integrated innovation in the medical device industry and a premier highland for industrial innovation.